the oncoprotein c-Myc
the oncoprotein c-Myc

Enrico Vanni, Ph.D.

Vice Chairman since 2011 | Lead Independent Director since January 1, 2021

Enrico Vanni, Ph.D.

Vice Chairman since 2011 | Lead Independent Director since January 1, 2021

the oncoprotein c-Myc

Nationality: Swiss | Year of birth: 1951

Enrico Vanni is an expert in business management, healthcare and technology who began his career as a research engineer at the International Business Machines Corp. (IBM) in the US. He later joined McKinsey & Co. in Switzerland, where he managed the Geneva office and led the firm’s European pharmaceutical practice. Since retiring in 2007, Mr. Vanni has continued to support leaders of pharmaceutical and biotechnology companies on core strategic challenges facing the healthcare industry.

Professional experience

  • Independent consultant supporting leaders of pharmaceutical and biotechnology companies (2008–2015)
  • Director, consulting in pharmaceutical, consumer and financial sectors, McKinsey & Co., Switzerland (1994–2007)
  • Head of the Geneva office, McKinsey & Co., Switzerland (1988–2004)

Mandates

  • Board member, Advanced Oncotherapy PLC, UK
  • Board member, Lombard Odier & Cie SA, Switzerland
  • Board member, Banque Privée BCP (Suisse) SA, Switzerland
  • Board member, Eclosion2 SA, Switzerland (2009–2017)
  • Board member, Alcon Inc., Switzerland (2010–2011)
  • Board member, Actavis PLC, Ireland (2010)

Education

  • Master of Business Administration, INSEAD, France
  • Doctorate in physical chemistry, University of Lausanne, Switzerland
  • Engineering degree in chemistry, Federal Polytechnic School of Lausanne, Switzerland

Key skills

  • Medicine/healthcare/R&D
  • Finance/accounting